

Zetiq Technologies Ltd. announces publication in the Molecular Pathology Journal

Zetiq Technologies Ltd. ("Zetiq"), a subsidiary of Bio-Light Ltd. (TASE: BOLT) and a developer of early cancer diagnosis tools, announces that the results of its pilot cervical biopsy clinical trial was accepted for publication in the Molecular pathology Journal.

The article details the results describing the successful clinical trial examining the use of the CellDetect technology for identification of cervical cancer in biopsy specimens.

"The acceptance of our clinical data for publication in this important peer reviewed journal is good testimony of the important progress we have made to date, accepted by respected members of the cancer diagnosis scientific community, and provides a growing awareness of the scientific community to our CellDetect technology", said Dr. Adi Elkeles, Zetiq CEO.

About Zetiq:

Zetiq Technologies Ltd. develops effective cancer diagnostic tools. A significant medical need exists for early stage diagnostic tools for screening, monitoring or diagnosing cancer. Zetiq offers unique advantages in this market with its proprietary CellDetect® technology for differential staining and morphological visualization to differentiate between non cancer cells and a wide variety of cancer indications. The Company's products alleviate the process of locating and identifying suspected cancer cells, reduce error, simplify the process and have a potential to be fully automated.

Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE: BOLT.

For further information please contact:

Dr. Adi Elkeles

CEO

Zetiq Technologies Ltd.

www.zetiq.co.il



adi@bio-light.co.il